Key Highlights
- Net loss per share was USD 0.89 against an estimate of a USD 0.69 loss.
- Net loss was USD 21.16 million, compared with USD 6.61 million.
- Research and development expenses were USD 15.02 million, compared with USD 2.83 million.
- Cash was USD 16.34 million and short-term investments were USD 15.97 million.
LeonaBio (NASDAQ:LONA) reported a net loss of USD 21.16 million for the third quarter of 2026, compared with USD 6.61 million in the prior-year quarter. Basic and diluted net loss per share attributable to common stockholders was USD 0.89, compared with USD 1.68, against an estimate of a USD 0.69 loss.
The company reported no Revenue in either period. Weighted average shares used in computing net loss per share were 23,740,719, compared with 3,943,887.
Third Quarter Results
Research and development expenses were USD 15.02 million, compared with USD 2.83 million. The change in Fair Value of a milestone Liability was a Credit of USD 411 thousand, and general and administrative expenses were USD 6.86 million, compared with USD 4.05 million.
Total operating expenses were USD 21.47 million, compared with USD 6.87 million, and the loss from operations was USD 21.47 million, compared with USD 6.87 million. Other income, net, was USD 303 thousand, compared with USD 263 thousand. The comprehensive loss attributable to common stockholders was USD 21.17 million, including an unrealized loss on available-for-sale securities of USD 3 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, Research and Development expenses were USD 38.98 million, compared with USD 10.79 million, and general and administrative expenses were USD 20.32 million, compared with USD 12.91 million. The change in fair value of the milestone liability was a credit of USD 1.17 million.
Total operating expenses were USD 58.13 million, compared with USD 23.70 million, and the loss from operations was USD 58.13 million, compared with USD 23.70 million. The company recorded a loss of USD 16.32 million on the change in fair value of the Sermonix pre-funded warrant. The net loss was USD 73.12 million, compared with USD 22.72 million, and net loss per share was USD 3.30, compared with USD 5.80. Weighted average shares were 22,181,938, compared with 3,919,258.
Balance Sheet and Going Concern Disclosure
Cash and cash equivalents were USD 16.34 million at September 30, 2026, compared with USD 69.28 million at December 31, 2025, and short-term investments were USD 15.97 million, compared with USD 19.06 million. Total Assets were USD 38.14 million, compared with USD 92.15 million.
Total current liabilities were USD 7.33 million, compared with USD 47.50 million, and total liabilities were USD 22.12 million, compared with USD 64.36 million. Additional paid-in Capital was USD 600.90 million, compared with USD 539.55 million. The filing discloses substantial doubt about the company's ability to continue as a going concern following the date of the quarterly report.
LeonaBio Q3 2026 Earnings: Key Takeaways
LeonaBio reported a third quarter 2026 net loss of USD 21.16 million and research and development expenses of USD 15.02 million. Cash and short-term investments totaled USD 16.34 million and USD 15.97 million at September 30, 2026.






Please wait processing your request...